US · Healthcare · Drug Manufacturers - General
EPS came in at 0.87 against a street estimate of 0.72 — a beat of 20.8%.
Analysts rate Pfizer Inc a buy (9 buy, 17 hold, 2 sell out of 28) with an average price target of $29.45.
CONFIDENT Pfizer beat Q2 earnings and raised full-year revenue guidance by $500M to $60.5–62.5B, driven by strong non-COVID portfolio growth (+5% operational). Launched products grew 27% (ex-onetime items). Cost-cutting expanded by $2.5B through 2029. Q2 2026 U.S. and select intl markets drove strong revenue growth. International benefits from government-secured vaccine contracts reducing seasonal volatility. Analysts pressed on trial design definitions (MEVPRO-1 success criteria, tilkumab vs Dupixent head-to-head power), portfolio growth rates (Padcev moderation), and long-term COVID trajectory post-low-infection year. Mgmt emphasized clinically meaningful endpoints, competitive differentiation data, and strong non-COVID offset. 2026-08-04…
Full summary in the app.
| Fund | Stake |
|---|---|
| BlackRock Inc | 9.29% |
| Vanguard Capital Management, LLC | 6.53% |
| State Street Corp | 5.39% |
| Geode Capital Management, LLC | 2.37% |
| Vanguard Portfolio Management, LLC | 2.09% |
| Fisher Asset Management, LLC | 1.91% |
| Morgan Stanley - Brokerage Accounts | 1.69% |
| NORGES BANK | 1.08% |
| Document | Date |
|---|---|
| Quarterly report · Q3 2026 HEADLINE NUMBERS • Third-quarter 2026 revenue was $16,583 million, compared with $16,654 million in the third quarter of 2025. • Third-quarter net i | 2026-11-03 |
| Board / officer change · Q4 2026 OTHER NOTABLE POINTS • Pfizer’s Board unanimously elected Cecile Guegan as Chief Financial Officer and Executive Vice President. • Guegan’s appointm | 2026-11-03 |
| Results announced · Q4 2026 HEADLINE NUMBERS • Third-quarter 2026 revenue was $16,583 million, compared with $16,654 million in the prior-year quarter; operationally, revenue wa | 2026-11-03 |
| Quarterly report · Q2 2026 PFIZER INC. FORM 10-Q SUMMARY For Quarterly Period Ended June 28, 2026 --- HEADLINE NUMBERS • Total Revenues (Six Months): $29,484 million vs. $28, | 2026-08-04 |
| Results announced · Q3 2026 PFIZER Q2 2026 EARNINGS SUMMARY HEADLINE NUMBERS • Q2 2026 revenues: $15.0 billion, up 3% reported (1% operational growth) • Adjusted diluted EPS: $ | 2026-08-04 |
| Reg FD disclosure · Q2 2026 PFIZER INC. - FORM 8-K SUMMARY (June 18, 2026) HEADLINE NUMBERS • 2026 Full-Year Revenue Guidance: $59.5 billion to $62.5 billion (reaffirmed) • 202 | 2026-06-18 |
| Board / officer change · Q2 2026 PFIZER INC. - FORM 8-K SUMMARY (June 18, 2026) HEADLINE NUMBERS • No financial metrics, earnings data, or numerical business results provided in this | 2026-06-18 |
| Quarterly report · Q1 2026 PFIZER INC. – Q1 2026 (10-Q) SUMMARY FOR RETAIL INVESTORS HEADLINE NUMBERS • Total Revenues (Q1 2026): $14,451 million vs. $13,715 million (Q1 2025) | 2026-05-05 |
Readable in the app.
| Action | Detail | Date |
|---|---|---|
| Dividend | $0.43 / share ex-date Nov 6, 2026 · pay Dec 7, 2026 | 2026-11-06 |
| Dividend | $0.43 / share ex-date Jul 24, 2026 · pay Sep 1, 2026 | 2026-07-24 |
| Dividend | $0.43 / share ex-date May 8, 2026 · pay Jun 12, 2026 | 2026-05-08 |
| Dividend | $0.43 / share ex-date Jan 23, 2026 · pay Mar 6, 2026 | 2026-01-23 |
| Dividend | $0.43 / share ex-date Nov 7, 2025 · pay Dec 1, 2025 | 2025-11-07 |
| Announcement | Date |
|---|---|
| Reaffirms full-year 2026 revenue and EPS guidance following CFO transition Pfizer announced that its Chief Financial Officer is transitioning (departing), but the company immediately reaffirmed its full-year 2026 financial guidance, suggesting management confidence | 2026-06-18 |
| Full-year 2026 guidance provided; 2025 revenue guidance revised On December 16, 2025, Pfizer issued an 8-K filing disclosing that it provided 2026 full-year guidance and revised its 2025 revenue guidance to investors. The company reaffirmed all other com | 2025-12-16 |
| Completed acquisition of Metsera for approximately $7.0 billion in cash Pfizer completed its acquisition of Metsera, Inc. on November 13, 2025, for an enterprise value of approximately $7.0 billion. Shareholders received $65.60 per share in cash at closing, plus | 2025-11-13 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Pfizer Inc — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.